Invasive Ductal Carcinoma of the Breast: Understanding Your Pathology Report

by Jason Wasserman MD PhD FRCPC and Zuzanna Gorski MD FRCPC
July 2, 2026

Invasive ductal carcinoma is the most common type of breast cancer. It starts in the epithelial cells lining the milk ducts of the breast and grows into the surrounding breast tissue. Left untreated, it can spread to other parts of the body, including the lymph nodes, bones, and lungs.

The name of this cancer is changing. The newer term used in many pathology reports is invasive breast carcinoma of no special type (NST), but “invasive ductal carcinoma” remains in wide use, and both names describe the same diagnosis. If your report uses the newer term, our companion article on invasive breast carcinoma (no special type) covers the same information.

This article will help you understand the findings in your pathology report, what the terms mean, what the numbers indicate, and why each piece of information matters for your care. If you had a breast biopsy or surgery, you may also find our guide to understanding your breast biopsy report helpful.

What causes invasive ductal carcinoma?

The exact cause of invasive ductal carcinoma is not known, but several factors increase the risk. Inherited gene changes, particularly in BRCA1 or BRCA2, substantially raise the risk of breast cancer, especially in people with a family history. Hormonal factors also play a role: starting menstruation early, going through menopause late, having no children or a first child after age 30, and using hormone replacement therapy are all associated with increased risk.

Risk also rises with age, especially after 50. A personal history of breast cancer or of a precancerous condition such as atypical ductal hyperplasia, or a prior diagnosis of ductal carcinoma in situ (DCIS), a non-invasive form of breast cancer confined to the ducts, increases the chance of developing invasive cancer. Prior chest radiation, especially in childhood or young adulthood, is another established risk factor. Lifestyle factors, including alcohol use, obesity, and physical inactivity, also contribute. Most breast cancers occur in people with no identifiable inherited cause.

What are the symptoms of invasive ductal carcinoma?

Many invasive ductal carcinomas are found on a screening mammogram before they cause symptoms. When symptoms do occur, the most common is a new lump or mass in the breast, often firm and irregular but sometimes soft or round. Other symptoms include changes in the size or shape of the breast, dimpling or redness of the skin, nipple inversion or discharge (especially bloody discharge), persistent pain in one area of the breast, and swelling of the breast without a lump. A lump or swelling in the lymph nodes under the arm or near the collarbone may also be a sign of invasive ductal carcinoma.

How is the diagnosis made?

The diagnosis of invasive ductal carcinoma is usually made after a small sample of the tumor is removed in a procedure called a biopsy, most often a core needle biopsy performed because of an abnormal mammogram or a lump felt on examination. The tissue is examined under a microscope by a pathologist, who confirms the diagnosis by finding cancer cells that have broken through the wall of the duct and are growing into the surrounding breast tissue. The same sample is also tested for the hormone receptors and HER2, described in the biomarker section below. After the biopsy confirms cancer, surgery to remove the entire tumor is typically recommended, and imaging such as ultrasound, mammogram, or breast MRI is used to measure the size and extent of the tumor before treatment.

Nottingham histologic grade

The Nottingham histologic grade (also called the modified Scarff-Bloom-Richardson grade) is one of the most important findings in an invasive ductal carcinoma pathology report. It describes how abnormal the cancer cells look and how quickly they are growing, information used to predict how the tumor is likely to behave and to guide treatment decisions. The grade is calculated by scoring three microscopic features, each on a scale of 1 to 3:

Tubule formation — How much of the tumor forms round, gland-like structures called tubules, which resemble normal breast tissue. A score of 1 means most cells form tubules; a score of 3 means very few tubules are present.
Nuclear pleomorphism — How variable and abnormal the nuclei (the center of each cell) look compared with normal breast cells. A score of 1 means the nuclei are relatively uniform; a score of 3 means they are markedly enlarged and irregular.
Mitotic count — How many cells are actively dividing (mitotic figures) in a defined area of the tumor. A higher count means the tumor is growing more quickly.

The three scores are added together (total range 3 to 9) to determine the overall grade:

Grade 1 (low grade) — Total score 3 to 5. Cancer cells closely resemble normal cells and tend to grow slowly. Associated with a more favorable outlook.
Grade 2 (intermediate grade) — Total score 6 or 7. Cancer cells show moderate abnormality and grow at an intermediate rate.
Grade 3 (high grade) — Total score 8 or 9. Cancer cells look distinctly abnormal and tend to grow and spread more quickly. This grade may lead the team to consider more intensive treatment.

Ductal carcinoma in situ (DCIS) in the same specimen

A pathology report for invasive ductal carcinoma may also mention ductal carcinoma in situ (DCIS). DCIS refers to abnormal cells confined to the milk ducts that have not yet broken into the surrounding breast tissue. Finding DCIS next to invasive ductal carcinoma is common and supports the understanding that the invasive cancer developed from a pre-existing in situ lesion. The extent of DCIS (how large an area it involves) and its grade may be reported separately, because these factors can influence surgical decisions.

Micropapillary features

An invasive ductal carcinoma report may note that the tumor has micropapillary features, meaning small clusters of tumor cells appear to float in open spaces under the microscope. This growth pattern matters because tumors with micropapillary features are more likely to enter nearby lymphatic vessels and reach the lymph nodes. When more than 90% of the tumor shows this pattern, it is classified as a separate subtype called invasive micropapillary carcinoma, which may carry specific treatment implications. Studies show these tumors have a higher chance of axillary lymph node involvement, although this does not necessarily worsen long-term survival when compared stage-for-stage with other invasive ductal carcinomas.

Mucinous features

When tumor cells are surrounded by large amounts of mucin (a gel-like substance), a report of invasive ductal carcinoma may describe mucinous features. If more than 90% of the tumor is mucinous, it is classified as invasive mucinous carcinoma, a distinct subtype with a generally more favorable outlook that tends to grow slowly and is less likely to spread to lymph nodes. When the tumor has a mix of mucinous and non-mucinous areas, its behavior depends on the proportions and on other tumor features.

Tumor size

Tumor size is one of the most important factors in invasive ductal carcinoma. It is used to determine the pathologic tumor stage (pT, described in the staging section below), and larger tumors are more likely to metastasize to lymph nodes and other organs. The final tumor size can only be measured accurately after the entire tumor has been removed at surgery, so it appears in the surgical specimen report rather than in a biopsy report.

Tumor extension

Invasive ductal carcinoma begins inside the breast, but in some cases the tumor grows into the overlying skin or the muscles of the chest wall. This is called tumor extension. Its presence is associated with a higher risk of local recurrence and distant spread, and it raises the pathologic tumor stage to pT4.

Lymphovascular invasion

In invasive ductal carcinoma, lymphovascular invasion (LVI) means cancer cells have entered small blood vessels or lymphatic channels near the tumor. These vessels can act as pathways for cancer cells to travel to the lymph nodes or other organs. Your report will describe this as “present” (or “positive”) or “absent” (or “negative”). When lymphovascular invasion is present, the risk of spread and recurrence is higher, and the team may discuss additional treatment such as chemotherapy or radiation therapy.

Surgical margins

A margin is the edge of the tissue removed during surgery for invasive ductal carcinoma. The pathologist examines the margins to determine whether the entire tumor was removed. Margins are assessed only after surgery that removes the whole tumor (a lumpectomy or mastectomy), not after a biopsy.

Negative margin — No cancer cells are seen at the cut edge. This is the goal of surgery and is associated with a lower risk of local recurrence.
Positive margin — Cancer cells are present at the cut edge, meaning some cancer may remain. Additional surgery or radiation is usually discussed.

Even when all margins are negative, the report may include a measurement of how close the nearest tumor cells came to the edge. A wider negative margin generally lowers the risk of recurrence.

Lymph nodes

Lymph nodes are small immune organs that filter fluid and can trap cancer cells. In invasive ductal carcinoma, cancer that spreads often travels first to the axillary lymph nodes (under the arm), so these nodes are removed during surgery and examined under the microscope. Your report will include the number of lymph nodes examined, the number that contain cancer, and the size of any cancer deposits.

The size of the largest deposit is described using three terms:

Isolated tumor cells — Clusters no larger than 0.2 mm. These are not counted as positive for staging and generally have little effect on treatment decisions.
Micrometastasis — A deposit larger than 0.2 mm but not larger than 2 mm, reported as pN1mi. May slightly increase the risk of recurrence.
Macrometastasis — A deposit larger than 2 mm. Associated with a higher risk of spread and typically leading to more intensive treatment, such as chemotherapy or radiation to the lymph node region.

Your report may also mention extranodal extension, meaning cancer has broken through the outer capsule of a lymph node into the surrounding tissue, a finding associated with a higher recurrence risk. The terms sentinel lymph node (the first node in the drainage chain from the breast) and non-sentinel axillary lymph node (those further along the chain) may also appear.

Biomarker and molecular testing

Biomarker testing is an essential part of every invasive ductal carcinoma workup. The results directly determine which treatments are most likely to work and help estimate the risk of recurrence. Every invasive ductal carcinoma is tested for the estrogen receptor, the progesterone receptor, and HER2.

Estrogen receptor (ER) and progesterone receptor (PR)

Estrogen receptor (ER) and progesterone receptor (PR) are proteins found in some breast cancer cells that enable them to respond to the hormones estrogen and progesterone. Tumors that carry these receptors use the hormones to fuel their growth. ER and PR are tested by immunohistochemistry on a biopsy or surgical specimen. Your report will include:

Percentage of positive cells — For example, “80% ER-positive” means 80% of the cancer cells carry the estrogen receptor.
Staining intensity — Described as weak, moderate, or strong, reflecting the amount of receptor protein present.
Overall score — Some reports use the Allred score or H-score, which combine the percentage and intensity into a single number.

A cancer is considered hormone receptor-positive if ER or PR is present in at least 1% of cells. These cancers tend to grow more slowly and usually respond well to hormone-blocking therapies such as tamoxifen or aromatase inhibitors (anastrozole, letrozole, exemestane), which reduce the chance of recurrence. Tumors with ER positivity between 1% and 10% are reported as ER low positive; they still benefit from hormone therapy more than ER-negative cancers but are managed with this lower level of expression in mind.

When ER, PR, and HER2 are all negative, the tumor is called triple-negative breast cancer. Triple-negative cancers do not respond to hormone therapy or HER2-targeted drugs, so chemotherapy is the mainstay of systemic treatment. Immunotherapy (pembrolizumab) is added for many triple-negative cancers, guided by PD-L1 testing in the advanced setting, as described below.

HER2

HER2 (human epidermal growth factor receptor 2) is a protein that helps control cell growth. In some invasive ductal carcinomas, the HER2 gene is amplified, meaning extra copies are present and the cancer cells produce too much HER2 protein. These tumors, called HER2-positive, often grow more quickly but respond very well to HER2-targeted therapies such as trastuzumab (Herceptin), pertuzumab, and trastuzumab-deruxtecan. You can read more in our article on HER2 in breast cancer.

HER2 is tested in two steps. Step 1 is immunohistochemistry (IHC), which measures the amount of HER2 protein on the surface of the tumor cells and is reported as a score:

IHC 0, no staining (HER2-negative) — No visible membrane staining. HER2-targeted therapies are not effective.
IHC 0, faint staining (HER2-ultralow) — Faint, incomplete membrane staining in 10% or fewer tumor cells. Still HER2-negative by standard criteria, but these tumors may respond to newer antibody-drug conjugates in hormone receptor-positive metastatic disease.
IHC 1+ (HER2-low) — Faint, incomplete membrane staining in more than 10% of cancer cells. Considered HER2-negative by traditional criteria, but HER2-low cancers may be eligible for trastuzumab-deruxtecan in the metastatic setting.
IHC 2+ (equivocal) — Weak to moderate complete membrane staining in more than 10% of tumor cells. The result is borderline, and in situ hybridization is required. If that test is negative, the tumor is reclassified as HER2-low.
IHC 3+ (HER2-positive) — Strong, complete membrane staining in more than 10% of cancer cells. HER2-targeted therapy is likely to help.

Step 2 is in situ hybridization (ISH), performed when the IHC result is 2+. This test counts the number of HER2 gene copies inside the tumor cells using fluorescent or silver probes and compares them with a reference point on the same chromosome (CEP17). A result showing extra copies (amplified) confirms a HER2-positive tumor, while a normal copy number (not amplified) confirms a HER2-negative tumor, reclassified as HER2-low if the IHC was 1+ or 2+. Reports may describe the ISH result using one of five groups defined by international guidelines; the pathologist combines the IHC and ISH results to give the final HER2 classification. Because the differences among HER2-negative, HER2-low, and HER2-ultralow now affect treatment options, pathologists report these categories carefully.

Molecular subtype

Together, the ER, PR, and HER2 results place invasive ductal carcinoma into a molecular subtype that shapes the treatment plan: hormone receptor-positive/HER2-negative (the most common), HER2-positive, or triple-negative. This subtype, combined with the stage and grade, determines which systemic treatments are considered.

Genomic testing (gene expression profiling)

In addition to the protein-based biomarkers above, many patients with hormone receptor-positive, HER2-negative early invasive ductal carcinoma have a genomic test that measures the activity of a panel of genes to estimate the risk of recurrence and predict the benefit of chemotherapy. These results may appear in the pathology report or be reported separately by the oncologist:

21-gene recurrence score (Oncotype DX) — Reports a score from 0 to 100. A low score suggests a low risk of recurrence and that chemotherapy is unlikely to add benefit beyond hormone therapy; a high score suggests the opposite.
70-gene signature (MammaPrint) — Classifies the tumor as low risk or high risk for distant recurrence.

Additional testing in advanced or recurrent disease

When invasive ductal carcinoma is advanced, recurrent, or has spread to other organs, a broader panel of molecular tests, often performed by next-generation sequencing, may identify changes that open up specific treatments. An inherited (germline) change in BRCA1 or BRCA2, or in the related gene PALB2, in a HER2-negative cancer may indicate benefit from a PARP inhibitor such as olaparib or talazoparib; because these changes can be inherited, a positive result usually leads to referral for genetic counseling. In hormone receptor-positive, HER2-negative disease, a PIK3CA change may indicate benefit from a PI3K inhibitor (alpelisib or inavolisib), and a PIK3CA, AKT1, or PTEN change may indicate benefit from the AKT inhibitor capivasertib. A change in the ESR1 gene, a common reason these cancers stop responding to certain hormone therapies, may indicate a switch to the oral drug elacestrant. In triple-negative breast cancer, PD-L1 testing (reported as a Combined Positive Score, generally 10 or higher) helps determine eligibility for the immunotherapy drug pembrolizumab; our overview of PD-L1 testing in cancer explains this in more detail. Rarely, a breast cancer carries a marker that qualifies for a treatment approved across cancer types, such as mismatch repair deficiency, a high tumor mutational burden, or an NTRK gene fusion.

For more information, visit our Biomarkers and Genetic Testing section.

Treatment effect and residual cancer burden

If you received chemotherapy, HER2-targeted therapy, or hormone therapy before surgery for invasive ductal carcinoma (called neoadjuvant therapy), your pathology report will describe how much tumor remains in the breast and lymph nodes, known as the treatment effect. The most commonly used measure is the residual cancer burden (RCB) index, which combines the size of the tumor bed, the percentage of remaining cancer cells, and the extent of lymph node involvement into a single score:

RCB-0 (pathologic complete response) — No residual invasive cancer in the breast or lymph nodes. The most favorable result, associated with the highest chance of long-term survival without recurrence.
RCB-I (minimal residual disease) — Very little cancer remains.
RCB-II (moderate residual disease) — A moderate amount of cancer remains.
RCB-III (extensive residual disease) — A large amount of cancer remains, with a higher risk of recurrence; additional treatment after surgery is often considered.

For HER2-positive and triple-negative breast cancers in particular, the degree of pathologic response to neoadjuvant therapy is one of the strongest predictors of long-term outcome.

Pathologic stage (pTNM)

Invasive ductal carcinoma is staged using the TNM staging system from the American Joint Committee on Cancer (AJCC), 8th edition, based on examination of the surgical specimen. TNM considers the primary tumor (T), lymph node involvement (N), and distant metastasis (M). The pathologist determines the pT and pN stages from the tissue; the M stage is determined by imaging. For breast cancer, the AJCC 8th edition also assigns a prognostic stage that combines the anatomic TNM with the grade and the ER, PR, and HER2 results, so tumor biology, not size alone, shapes the final stage.

Tumor stage (pT)

pT0 — No primary tumor found in the surgical specimen (may occur after a complete response to neoadjuvant therapy).
pT1mi — Tumor 1 mm or smaller.
pT1a — Tumor larger than 1 mm but 5 mm or smaller.
pT1b — Tumor larger than 5 mm but 10 mm or smaller.
pT1c — Tumor larger than 10 mm but 20 mm or smaller.
pT2 — Tumor larger than 20 mm but 50 mm or smaller.
pT3 — Tumor larger than 50 mm.
pT4a — Tumor has grown into the chest wall.
pT4b — Tumor has grown into the skin, causing ulceration or satellite skin nodules.
pT4c — Both pT4a and pT4b are present.
pT4d — Inflammatory breast cancer (redness and swelling of the breast skin).

Nodal stage (pN)

pN0 — No cancer in any lymph nodes examined.
pN0(i+) — Isolated tumor cells only (clusters 0.2 mm or smaller), not counted as positive.
pN1mi — Micrometastases only (larger than 0.2 mm up to 2 mm).
pN1a — Cancer in 1 to 3 axillary lymph nodes, with at least one deposit larger than 2 mm.
pN1b — Cancer in internal mammary sentinel nodes on the same side (excluding isolated tumor cells).
pN2a — Cancer in 4 to 9 axillary lymph nodes.
pN2b — Cancer in internal mammary lymph nodes without axillary involvement.
pN3a — Cancer in 10 or more axillary lymph nodes, or in nodes below the collarbone.
pN3b — Cancer in internal mammary lymph nodes together with axillary lymph nodes.
pN3c — Cancer in supraclavicular lymph nodes (above the collarbone).

What is the prognosis for invasive ductal carcinoma?

The prognosis for invasive ductal carcinoma depends on several factors working together, and no single finding tells the whole story. Overall, outcomes are favorable, especially when the cancer is found early. Your team will consider all of the following:

Stage — The most important predictor. Cancers found early and confined to the breast (pT1, pN0) have a five-year survival rate exceeding 95%. Outcomes vary more widely once the cancer has spread to lymph nodes or distant organs.
Grade — Higher-grade (grade 3) tumors grow faster and carry a higher risk of recurrence than grade 1 tumors.
Hormone receptor and HER2 status — ER/PR-positive tumors generally respond well to hormone therapy and have a favorable outlook. HER2-positive cancers tend to grow more quickly but respond well to HER2-targeted treatment. Triple-negative cancers are more difficult to treat and have a higher short-term recurrence risk, but they can still be curable, especially when a complete pathologic response is achieved with neoadjuvant chemotherapy.
Lymphovascular invasion — Its presence increases the risk of lymph node involvement and distant spread.
Surgical margins — Negative margins with adequate distance reduce the risk of local recurrence.
Genomic test results — Tests such as the 21-gene recurrence score refine the estimate of recurrence risk beyond standard pathologic features, particularly for hormone receptor-positive, HER2-negative cancers.
Response to neoadjuvant therapy — Achieving a pathologic complete response (RCB-0) is associated with significantly better long-term outcomes, particularly for HER2-positive and triple-negative breast cancers.

What happens after this diagnosis?

After a diagnosis of invasive ductal carcinoma, care is usually coordinated by a team that may include a breast surgeon, a medical oncologist, a radiation oncologist, a pathologist, a radiologist, and, when inherited risk is a concern, a genetic counselor. The pathology findings guide which options the team considers, rather than dictating a single path. Surgery (breast-conserving surgery or mastectomy) removes the tumor, and lymph nodes are usually sampled at the same time. Radiation therapy is often considered after breast-conserving surgery and sometimes after mastectomy. Systemic treatment is chosen based on the report: hormone therapy for hormone receptor-positive cancers, HER2-targeted therapy for HER2-positive cancers, chemotherapy based on stage, grade, subtype, and genomic results, and immunotherapy for many triple-negative cancers. After treatment, follow-up includes regular examinations and imaging, along with attention to bone health, menopausal symptoms, and, when relevant, fertility and genetic counseling.

Questions to ask your doctor

What was the size and Nottingham grade of my tumor?
What is the pathologic stage of my cancer (pT and pN)?
Were any lymph nodes involved, and if so, how many and what size were the deposits?
Were the surgical margins clear, and was the tumor completely removed?
Is lymphovascular invasion present?
What are my hormone receptor (ER and PR) results, and how do they affect my treatment?
What is my HER2 status (negative, ultralow, low, or positive), and does it change my treatment options?
Is my tumor triple-negative, and what does that mean for treatment?
Was DCIS found alongside the invasive cancer, and does its extent affect surgery recommendations?
Will I need genomic testing such as Oncotype DX or MammaPrint, and how would the result change my treatment?
If I received treatment before surgery, what was my residual cancer burden score, and what does it mean?
Should I be referred for genetic counseling to evaluate for BRCA1/2 mutations or other inherited mutations?
What additional treatment is recommended: surgery, radiation, chemotherapy, hormone therapy, targeted therapy, immunotherapy, or a combination?
What follow-up schedule and surveillance imaging will I need?